Shanghai Shenqi Medical's SQ-Kyrin-M® Transcatheter Mitral Valve Clip System Receives NMPA Approval

Recently, Shanghai Shenqi Medical Technology Co., Ltd. (hereinafter referred to as "Shenqi Medical"), independently developedQilin-M^®（SQ-Kyrin-M^®) The transcatheter mitral valve clip system has been officially approved for marketing by the National Medical Products Administration (NMPA) (Registration Certificate No. 20263130777).

Qilin-M^®Composed of a mitral valve clip and delivery system, and a guidance system, using a percutaneous approach. It is suitable for patients with degenerative mitral regurgitation (MR≥3+) who are assessed by a cardiac team as having a high surgical risk and whose mitral valve anatomy is appropriate. This product previously entered the National Medical Products Administration’s "green channel" for innovative products in September 2021 through the "Special Review Procedure for Innovative Medical Devices." QiLin-M^®The successful approval marks an important milestone for Shenqi Medical in the field of interventional treatment for structural heart disease, and is a profound testament to Shenqi Medical's commitment to the philosophy of "Innovation·Protecting the Heart".

As a medical enterprise rooted in China, Shenqi Medical adheres to the concept of "Innovation · Heart Protection" and always takes "better meeting the rapidly growing healthcare needs of the Chinese market" as its mission. By developing innovative and high-quality cardiac and vascular interventional products, it provides comprehensive solutions in the field of cardiovascular disease treatment, benefiting more patients in China. In the future, Shenqi Medical will position and develop its products for the global market, actively participate in global competition in related fields, and commit to launching more high-quality and advanced medical device products to provide more comprehensive disease treatment solutions for patients both domestically and internationally.